Latest revenue
$2.6M
as of 2026-03-31
Latest net income
$2.2M
as of 2026-03-31
Net margin
85.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.6M
- Enterprise value
- $1.6M
- P/E (trailing)
- 14.8×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.46
- 52-wk low
- $0.10
- Beta
- —
- Shares out
- 7.4M
5-year trend
What this company does
ITEM 1. BUSINESS Company Overview Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. All intercompany accounts and transactions have been eliminated. The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices for ophthalmic applications. The Company…
AI summary unavailable — showing raw filing excerpt
Generated from ESMC's filing dated 2025-09-29
Key risks
ITEM 1A. RISK FACTOR In addition to other information contained in this report on Form 10-K, the following Risk Factors should be considered carefully in evaluating our business. If any of the following risks actually occur, our financial condition and results of operations could be materially and adversely affected. Financial Risks Due to the Company’s history of operating losses, we have compiled these financial statements based on the assumption there is substantial doubt related to our ability to continued as a going concern. Our operations are subject to a number of factors that can affect our operating results and financial condition. Such factors include, but are not limited to: the…
AI summary unavailable — showing raw filing excerpt
Generated from ESMC's filing dated 2025-09-29
Profitability
Operating margin
1.1%
226.8%Net margin
0.9%
183.8%Return on equity
5.5%
179.6%Return on assets
2.1%
180.3%Leverage
Debt / equity
1.61×
1.4%Long-term debt / equity
0.07×
7.9%Debt / assets
61.6%
0.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $2.6M | -24.9% | $2.2M | +721.9% | 85.5% |
Q4 2025 2025-12-31 | $3.6M | +11.5% | $97.7K | -54.3% | 2.7% |
Q3 2025 2025-09-30 | $2.7M | -3.8% | $-239.9K | -844.5% | -9.0% |
Q2 2025 2025-06-30 | $2.6M | -26.0% | $-412.0K | -20.3% | -16.0% |
Q1 2025 2025-03-31 | $3.5M | +28.9% | $271.5K | +67.4% | 7.8% |
Q4 2024 2024-12-31 | $3.2M | +12.2% | $213.8K | +180.1% | 6.6% |
Q3 2024 2024-09-30 | $2.8M | -5.6% | $32.2K | +252.0% | 1.2% |
Q2 2024 2024-06-30 | $3.5M | — | $-342.5K | — | -9.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on ESMC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ESMC in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ESMC
No institutional holdings on file for ESMC yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once ESMC's latest filing finishes processing.